The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Sorafenib is an effective palliative treatment against hepatocellular carcinoma (HCC), however the oral tablet formulation is associated with severe side effects and low serum levels suggest delivery of insufficient doses. A drug-eluting bead formulation for catheter-directed delivery should increase tumor doses and decrease side effects. Thus, polylactide-co-glycolide (PLG) microspheres were developed...
Adoptive immunotherapy (AIT) with natural killer (NK) lymphocytes is a promising therapy for hepatocellular carcinoma (HCC). The purpose of this study was to test the hypotheses that superparamagnetic iron oxide (SPIO) nanoparticle labeling permits magnetic resonance imaging (MRI)-based quantification of NK delivery to HCC post infusion; intraarterial (IA) NK infusion demonstrates a therapeutic benefit...
The rationale for this study was to develop and validate methods to non-invasively quantify drug delivery to tumors. The ideal animal model of hepatocellular carcinoma (HCC) would have histological similarity to human HCC yet permit intraarterial (IA) delivery of therapies. The hypervascular McA-RH7777 tumor in the diminutive Buffalo rat resembles HCC histologically, while the N1S1 tumor in the larger...